编者按:近期,由北京白求恩公益基金会发起,多位内分泌领域核心专家牵头撰写完成的《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。这是中国首个专门针对SGLT2i联合二甲双胍治疗T2DM临床应用的指导性文件,为临床医生了解并规...
[13]Heerspink H,Stefánsson BV,Correa-Rotter R,et al.Dapagliflozin in patients with chronic kidney disease[J].N Engl J Med,2020,383(15):1436-1446.DOI:10.1056/NEJMoa2024816. [14]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or c...
Likewise, the Canadian guidelines [38] recommend that, in the absence of contraindications, patients with HFrEF be treated with combination therapy from the beginning, including one evidenced-based medication from each of the categories (ARNI, B-blocker, MRA, and SGLT2i) (strong recommendation; mo...
Demographic, clinical, biochemical and medication data were collected from medical charts and our local digital database:EVOLVE and CVWeb. Patients had to meet the DAPA-HF inclusion criteria to be deemed eligible for dapagliflozin therapy. Results Table 1 summarises the baseline clinical data and ...
[15]Osterberg L,Blaschke T.Adherence to medication[J].N Engl J Med.2005, 353(5):487-497.DOI:10.1056/NEJMra050100. 提醒:SGLT2i在中国尚未获得治疗肥胖/高血压适应症,尚未获批改善糖尿病患者心血管疾病风险/肾脏疾病风险的适应症。使用前请参考相关药品说明书。